John Oyler net worth and biography

John Oyler Biography and Net Worth

CEO of BeiGene
John V. Oyler is our Co-Founder and Chairman, and has served as our Chief Executive Officer and a member of our Board of Directors since 2010. From 2005 to 2009, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology. From 1997 to 2002, Mr. Oyler was a Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. From 1997 to 1998, Mr. Oyler served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology‑focused biopharmaceutical company. Mr. Oyler joined the Board of Directors of the Biotechnology Innovation Organization (BIO) in 2019 and is a member of its Health Section Governing Board. He began his career as a management consultant at McKinsey & Company. Mr. Oyler received his B.S. from Ma ssachusetts Institute of Technology and MBA from Stanford University.

What is John Oyler's net worth?

The estimated net worth of John Oyler is at least $279.20 million as of September 20th, 2022. Mr. Oyler owns 2,070,913 shares of BeiGene stock worth more than $279,200,491 as of October 2nd. This net worth estimate does not reflect any other investments that Mr. Oyler may own. Additionally, Mr. Oyler receives an annual salary of $1,750,000.00 as CEO at BeiGene. Learn More about John Oyler's net worth.

How old is John Oyler?

Mr. Oyler is currently 54 years old. There are 5 older executives and no younger executives at BeiGene. Learn More on John Oyler's age.

What is John Oyler's salary?

As the CEO of BeiGene, Ltd., Mr. Oyler earns $1,750,000.00 per year. Learn More on John Oyler's salary.

How do I contact John Oyler?

The corporate mailing address for Mr. Oyler and other BeiGene executives is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. BeiGene can also be reached via phone at 861085148500 and via email at [email protected] Learn More on John Oyler's contact information.

Has John Oyler been buying or selling shares of BeiGene?

John Oyler has not been actively trading shares of BeiGene in the last ninety days. Most recently, John Oyler sold 30,520 shares of the business's stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $153.50, for a transaction totalling $4,684,820.00. Following the completion of the sale, the chief executive officer now directly owns 2,070,913 shares of the company's stock, valued at $317,885,145.50. Learn More on John Oyler's trading history.

Who are BeiGene's active insiders?

BeiGene's insider roster includes Timothy Chen (Director), Donald Glazer (Director), Jane Huang (CMO), Howard Liang (CFO), John Oyler (CEO), Julia Wang (CFO), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeiGene's active insiders.

Are insiders buying or selling shares of BeiGene?

During the last twelve months, insiders at the sold shares 15 times. They sold a total of 50,534 shares worth more than $8,840,091.52. The most recent insider tranaction occured on September, 20th when CEO John Oyler sold 30,520 shares worth more than $4,684,820.00. Insiders at BeiGene own 7.5 % of the company. Learn More about insider trades at BeiGene.

Information on this page was last updated on 9/20/2022.

John Oyler Insider Trading History at BeiGene

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/20/2022Sell30,520$153.50$4,684,820.002,070,913View SEC Filing Icon  
9/14/2021Sell195,477$93.87$18,349,425.992,267,161View SEC Filing Icon  
9/2/2021Sell24,499$328.21$8,040,816.793,694,720View SEC Filing Icon  
8/31/2021Sell111,081$110.13$12,233,350.53View SEC Filing Icon  
8/4/2021Sell80,847$150.97$12,205,471.594,385,979View SEC Filing Icon  
7/22/2021Sell69,216$71.82$4,971,093.125,849,945View SEC Filing Icon  
7/20/2021Sell43,695$132.26$5,779,100.705,849,945View SEC Filing Icon  
7/7/2021Sell300$325.23$97,569.00View SEC Filing Icon  
9/29/2020Sell54,303$280.39$15,226,018.178,927,570View SEC Filing Icon  
9/16/2020Sell27,275$254.77$6,948,851.759,633,509View SEC Filing Icon  
9/14/2020Sell19,739$250.25$4,939,684.759,633,509View SEC Filing Icon  
9/2/2020Sell61,042$233.21$14,235,604.8210,689,473View SEC Filing Icon  
8/31/2020Sell12,961$240.86$3,121,786.4610,689,473View SEC Filing Icon  
8/21/2020Sell40,788$240.19$9,796,869.7211,483,019View SEC Filing Icon  
8/19/2020Sell29,866$234.56$7,005,368.9611,483,019View SEC Filing Icon  
8/14/2020Sell8,705$211.15$1,838,060.7512,681,320View SEC Filing Icon  
8/12/2020Sell19,820$212.10$4,203,822.0012,681,320View SEC Filing Icon  
8/5/2020Sell17,254$223.27$3,852,300.5813,239,904View SEC Filing Icon  
8/3/2020Sell25,176$221.78$5,583,533.2813,464,206View SEC Filing Icon  
7/22/2020Sell27,748$238.34$6,613,458.3213,991,473View SEC Filing Icon  
7/20/2020Sell28,762$251.85$7,243,709.7014,352,197View SEC Filing Icon  
7/8/2020Sell17,529$201.39$3,530,165.3115,069,472View SEC Filing Icon  
7/6/2020Sell17,362$197.11$3,422,223.8215,069,472View SEC Filing Icon  
7/1/2020Sell3,816$191.57$731,031.1215,770,354View SEC Filing Icon  
6/29/2020Sell1,435$192.60$276,381.0015,770,354View SEC Filing Icon  
6/24/2020Sell14,381$187.34$2,694,136.5415,838,617View SEC Filing Icon  
6/22/2020Sell10,281$182.43$1,875,562.8315,838,617View SEC Filing Icon  
5/1/2020Sell4,635$141.43$655,528.0516,366,833View SEC Filing Icon  
12/17/2019Sell62,259$160.62$10,000,040.5816,411,788View SEC Filing Icon  
7/8/2019Sell3,106$126.87$394,058.2217,221,155View SEC Filing Icon  
5/1/2019Sell2,824$125.18$353,508.32View SEC Filing Icon  
3/6/2019Sell25,499$151.73$3,868,963.2717,298,245View SEC Filing Icon  
3/4/2019Sell4,588$152.01$697,421.8817,298,245View SEC Filing Icon  
12/10/2018Sell4,138$135.78$561,857.6417,420,172View SEC Filing Icon  
11/28/2018Sell29,195$143.66$4,194,153.7017,420,172View SEC Filing Icon  
11/26/2018Sell9,078$139.06$1,262,386.6817,420,172View SEC Filing Icon  
7/16/2018Sell2,550$164.12$418,506.00View SEC Filing Icon  
3/2/2018Sell99,000$145.63$14,417,370.0093,883View SEC Filing Icon  
2/28/2018Sell34,338$146.69$5,037,041.2293,883View SEC Filing Icon  
12/26/2017Sell20,137$96.46$1,942,415.02110,179View SEC Filing Icon  
12/8/2017Sell144,000$93.95$13,528,800.00255,137View SEC Filing Icon  
12/6/2017Sell31,446$92.29$2,902,151.34255,137View SEC Filing Icon  
11/29/2017Sell85,906$84.66$7,272,801.96332,697View SEC Filing Icon  
11/27/2017Sell16,581$86.76$1,438,567.56332,697View SEC Filing Icon  
11/15/2017Sell150,957$80.50$12,152,038.50491,891View SEC Filing Icon  
11/13/2017Sell25,054$83.06$2,080,985.24491,891View SEC Filing Icon  
7/6/2017Sell219,400$64.82$14,221,508.00212,055View SEC Filing Icon  
6/23/2017Sell98,500$44.16$4,349,760.0088,535View SEC Filing Icon  
5/1/2017Sell36,149$40.47$1,462,950.03147,440View SEC Filing Icon  
3/20/2017Sell31,989$39.39$1,260,046.71197,640View SEC Filing Icon  
3/6/2017Sell108,999$40.91$4,459,149.09273,385View SEC Filing Icon  
2/21/2017Sell64,963$40.55$2,634,249.65378,383View SEC Filing Icon  
See Full Table

John Oyler Buying and Selling Activity at BeiGene

This chart shows John Oyler's buying and selling at BeiGene by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BeiGene Company Overview

BeiGene logo
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $134.82
Low: $133.31
High: $137.78

50 Day Range

MA: $169.01
Low: $131.80
High: $202.24

2 Week Range

Now: $134.82
Low: $118.18
High: $392.30

Volume

257,250 shs

Average Volume

218,775 shs

Market Capitalization

$13.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65